Valuation: Arsanis Inc

Market Cap 360M 315M 291M 268M 505M 34.69B 517M 3.47B 1.37B 16.96B 1.35B 1.32B 58.55B P/E 2026 *
-5.23x
P/E 2027 * -4.99x
Enterprise Value 271M 237M 219M 202M 380M 26.12B 389M 2.61B 1.03B 12.77B 1.02B 996M 44.09B EV / Sales 2026 *
28.3x
EV / Sales 2027 * 18.1x
Free-Float
92.32%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 60 -
Director of Finance/CFO 71 2025-08-11
President - 2025-08-11
Director TitleAgeSince
Chairman 71 2018-06-30
Director/Board Member 63 2018-09-30
Director/Board Member 65 2019-03-28
Change 5-day change 1-year change 3-year change Capi.($)
+27.91%-3.04% - - 360M
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average +2.73%+0.54%+28.54%+53.91% 397.23B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2026 *2027 *
Net sales 9.6M 8.4M 7.76M 7.14M 13.46M 924M 13.76M 92.51M 36.39M 452M 36.05M 35.26M 1.56B 10.26M 8.98M 8.3M 7.63M 14.38M 988M 14.71M 98.87M 38.89M 483M 38.53M 37.68M 1.67B
Net income -95.1M -83.23M -76.89M -70.74M -133M -9.16B -136M -916M -360M -4.48B -357M -349M -15.46B -109M -95.06M -87.82M -80.8M -152M -10.46B -156M -1.05B -412M -5.11B -408M -399M -17.65B
Net Debt -89M -77.89M -71.96M -66.2M -125M -8.57B -128M -858M -337M -4.19B -334M -327M -14.46B -174M -153M -141M -130M -245M -16.8B -250M -1.68B -661M -8.21B -655M -641M -28.36B
Logo Arsanis Inc
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-